DOCSLIB.ORG

Identification of Human Myometrial Target Genes of the Cyclic AMP

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Supplementary Figure 3b: Genes with altered expression levels of 2-fold or greater in response to over-expression of CREB in stably-transfected myometrial cell lines: main list (genes known or thought to be linked with myometrial activity). Gene Fold change Genbank Gene Fold change Genbank Cell adhesion Immunity proteins (complement/MHC/blood coagulation) cont’d SELE selectin E (endothelial adhesion molecule 1) 6.4 NM_000450 C4B complement component 4B 2.0 NM_000592 ICAM4 intercellular adhesion molecule 4, Landsteiner-Wiener blood group 3.0 NM_001544 C9 complement component 9 2.6 K02766.1 C1QA complement component 1, q subcomponent, alpha polypeptide 2.6 NM_015991 ICAM1 intercellular adhesion molecule 1 (CD54), human rhinovirus receptor 2.1 AA284705 Cytokines, hormones & receptors Cell Death IL18 interleukin 18 (interferon-gamma-inducing factor) 7.2 NM_001562 TNFRSF9 tumor necrosis factor receptor superfamily, member 9 5.2 BC006196.1 IL8 interleukin 8 6.7 AF043337.1 ARTS-1 type 1 tumor necrosis factor receptor shedding aminopeptidase regulator 3.1 BE551138 CCL23 chemokine (C-C motif) ligand 23 4.9 U58913.1 TNFRSF25 tumor necrosis factor receptor superfamily, member 25 2.9 U72763.1 PTGFR prostaglandin F receptor (FP) 3.9 NM_000959 TNFSF4 tumor necrosis factor (ligand) superfamily, member 4 (tax-transcriptionally 2.6 NM_003326 LHCGR luteinizing hormone/choriogonadotropin receptor 3.4 NM_000233 activated glycoprotein 1, 34kDa) OXTR oxytocin receptor 3.4 NM_000916 TNFAIP2 tumor necrosis factor, alpha-induced protein 2 2.4 AI862445 IL-17RC interleukin 17 receptor C 3.4 BF112057 TNFRSF1B tumor necrosis factor receptor superfamily, member 1B 2.1 NM_001066 DTR diphtheria toxin receptor (heparin-binding epidermal growth factor-like 3.3 M60278 growth factor) TNFRSF10C tumor necrosis factor receptor superfamily, member 10c, decoy without an 2.5 AF012536.1 CXCL11 chemokine (C-X-C motif) ligand 11 2.6 AF002985.1 intracellular domain CCL20 chemokine (C-C motif) ligand 20 2.1 NM_004591 Cell growth & maintenance ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 2.1 U95204.1 FGF18 fibroblast growth factor 18 5.0 AB007422.1 CCL24 chemokine (C-C motif) ligand 24 2.1 NM_002991 FGF17 fibroblast growth factor 17 4.2 NM_003867 CCL3 chemokine (C-C motif) ligand 3 2.1 NM_002983 PTN pleiotrophin (heparin binding growth factor 8, neurite growth-promoting 2.6 BC005916.1 CXCL12 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 2.5 NM_000609 factor 1) CCL15 chemokine (C-C motif) ligand 15 12.5 AF031587.1 IGFBP3 insulin-like growth factor binding protein 3 2.0 NM_000598.1 FGF6 fibroblast growth factor 6 5.0 NM_020996 Transport GAS1 growth arrest-specific 1 33.3 AW611727 SLC24A1 solute carrier family 24 (sodium/potassium/calcium exchanger), member 1 5.2 AB014602.1 SLC30A6 likely ortholog of mouse zinc transporter 6 3.9 NM_017964 Cell surface linked signal transduction ATP2C1 ATPase, Ca++ transporting, type 2C, member 1 2.2 AF225981.1 ITGB8 integrin, beta 8 4.5 NM_002214 SLC12A4 solute carrier family 12 (potassium/chloride transporters), member 4 2.0 AF047338.1 RGS10 regulator of G-protein signalling 10 3.1 AI744627 ATP1A3 ATPase, Na+/K+ transporting, alpha 3 polypeptide 2.3 NM_000703.1 RGS20 regulator of G-protein signalling 20 2.5 AF074979.1 SLC39A2 solute carrier family 39 (zinc transporter), member 2 3.0 NM_014579 ITGB2 integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated 2.4 NM_000211 antigen 1; macrophage antigen 1 (mac-1) beta subunit) G6PT glucose-6-phosphatase, transport (glucose-6-phosphate) protein 1 3.1 AF097831 ITGA4 integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) 2.4 NM_000885 ITGB4 integrin, beta 4 2.0 NM_000213 Non-classified / other LOC64182 similar to rat myomegalin (cAMP-responsive; localizes components 10.2 AB042557.1 KCNH2 potassium voltage-gated channel, subfamily H (eag-related), member 2 2.5 AB044806.1 of cAMP pathway) SCN11A sodium channel, voltage-gated, type XI, alpha polypeptide 3.3 AF150882.1 AQP4 aquaporin 4 6.3 U63622.1 2+ RGS12 regulator of G-protein signalling 12 3.3 AW170602 CAPN10 calpain 10 (Ca -dependent; cytoskeletal remodeling & signal transduction) 6.1 NM_023089 RGS14 regulator of G-protein signalling 14 3.3 AF037194.1 CALML3 calmodulin-like 3 5.6 M36707.1 CBX7 ESTs, Highly similar to potassium voltage-gated channel, 3.3 AV648364 TRPC4 transient receptor potential cation channel, subfamily C, member 4 4.3 NM_016179 Isk-related subfamily, gene 4; potassium voltage-gated channel-like ADRA1A adrenergic, alpha-1A-, receptor 4.1 D32202.1 protein, Isk-related subfamily [Homo sapiens] [H.sapiens] MEF2D MADS box transcription enhancer factor 2, polypeptide D 3.8 AL530331 KCNQ4 potassium voltage-gated channel, KQT-like subfamily, member 4 5.0 NM_004700 (myocyte enhancer factor 2D) (involved in muscle-specific and/or growth- factor related transcription) Developmental processes KCNK2 potassium channel, subfamily K, member 2 3.8 AF004711.1 HIST1H2BI H2B histone family, member K 3.6 NM_003525 SOX11 SRY (sex determining region Y)-box 11 2.6 AI360875 H4FN H4 histone, family 2 3.5 NM_003548 SOX4 SRY (sex determining region Y)-box 4 2.9 AI989477 LOC57086 smooth muscle cell-expressed and macrophage conditioned medium- 3.4 NM_020351 induced Intracellular signalling protein smag-64 KCNAB1 potassium voltage-gated channel, shaker-related subfamily, beta 3.8 U33428.1 H2BFB H2B histone family, member B 3.3 AL353759 member 1 KCNN2 potassium intermediate/small conductance calcium-activated channel, 2.9 NM_021614 SCN2B sodium channel, voltage-gated, type II, beta polypeptide 2.6 U87555.1 subfamily N, member 2 KCNJ12 potassium inwardly-rectifying channel, subfamily J, member 12 2.9 NM_021012 ARHGAP6 Rho GTPase activating protein 6 2.1 NM_006125 HIST1H2BL H2B histone family, member C 2.6 NM_003519 ARHGAP1 Rho GTPase activating protein 1 2.6 U62794.1 AKAP11; clone RP11-215B13 on chromosome 13 Contains the AKAP11 gene 2.5 AL136527 PRKA11; for A kinase (PRKA) anchor protein 11, part of a novel gene, AKAP220; a fumarate hydratase (FH) pseudogene, the 3' end of the DGKH Pregnancy AKAP220; gene for diacylglycerol kinase eta and a CpG Island PSG5 pregnancy specific beta-1-glycoprotein 5 3.6 NM_002781 FLJ11304; PSG3 pregnancy specific beta-1-glycoprotein 3 3.0 NM_021016 KIAA0629 PSG6 pregnancy specific beta-1-glycoprotein 6 2.7 M31125.1 ESR1 estrogen receptor 1 2.5 AF258450.1 CRHR2 corticotropin releasing hormone receptor 2 (may modulate 2.5 AF019381.1 myometrial inflammatory response) Extracellular matrix AKAP7 A kinase (PRKA) anchor protein 7 2.5 AF161075.1 MMP1 matrix metalloproteinase 1 (interstitial collagenase) 42.2 NM_002421 Putative endothelin receptor type B-like protein [Homo sapiens], 2.5 U87460.1 PCLO piccolo (presynaptic cytomatrix protein) 6.3 BC001304.1 mRNA sequence SMARCAL1 SWI/SNF related, matrix associated, actin dependent regulator of 5.3 NM_014140 HIST1H2BM H2B histone family, member E 2.5 NM_003521 chromatin, CCR6 Chemokine (C-C motif) receptor 6; chemokine (C-C) receptor 6; 2.4 NM_004367 subfamily a-like 1 G protein-coupled receptor 29; seven-transmembrane receptor, MMP23A matrix metalloproteinase 23A 4.7 NM_004659 lymphocyte, 22; COL13A1 collagen, type XIII, alpha 1 4.0 M33653.1 chemokine receptor-like 3 [Homo sapiens], mRNA sequence COL11A2 collagen, type XI, alpha 2 3.6 AL031228 GPRC5B G protein-coupled receptor, family C, group 5, member B 2.2 NM_016235 FCN2 ficolin (collagen/fibrinogen domain containing lectin) 2 (hucolin) 2.7 NM_015839 DF D component of complement (adipsin) 2.2 NM_001928 SOCS1 suppressor of cytokine signaling 1 2.2 NM_003745.1 COL5A1 collagen, type V, alpha 1 2.1 AI130969 AQP8 aquaporin 8 2.1 NM_001169 COL6A2 collagen, type VI, alpha 2 2.6 AY029208.1 H2AFC H2A histone family, member C 2.1 NM_003509.1 COL16A1 collagen, type XVI, alpha 1 2.9 NM_001856 HIST1H1E H1 histone family, member 4 2.1 NM_005321 COL4A2 collagen, type IV, alpha 2 2.9 AK025912.1 CAV2 caveolin 2 (functionally regulates G protein alpha subunits) 2.1 AA150110 BGN biglycan 2.9 AA845258 ADRB2 adrenergic, beta-2-, receptor, surface 2.0 NM_000024 COL6A1 collagen, type VI, alpha 1 3.2 BE350145 MATN1 matrilin 1, cartilage matrix protein 3.3 NM_002379 CCR3 chemokine (C-C motif) receptor 3 2.0 NM_001837 COL4A3 collagen, type IV, alpha 3 (Goodpasture antigen) 5.6 U02520.1 TRPC5 transient receptor potential cation channel, subfamily C, member 5 2.0 NM_012471 COL18A1 collagen, type XVIII, alpha 1 8.3 NM_030582.1 ADRA2A adrenergic, alpha-2A-, receptor 2.1 AF284095.1 GPR86 G protein-coupled receptor 86 2.1 NM_023914 Chromatin H1FX H1 histone family, member X 2.2 NM_006026 OXT oxytocin, prepro- (neurophysin I) 2.2 NM_000915 SMARCF1 SWI/SNF related, matrix associated, actin dependent regulator of chromatin,3.6 NM_006015 subfamily f, member 1 H2AFY2 H2A histone family, member Y2 2.3 NM_018649 PTGER3 prostaglandin E receptor 3 (subtype EP3) 2.3 L27489.1 Cytoskeletal proteins PCDHGA8 protocadherin gamma subfamily A, 8 (Ca2+ dependent cell adhesion) 2.4 AB002325.1 SVIL Supervillin (actin binding) 2.4 AW872377 LOC51036 retinoic acid receptor-beta associated open reading frame 2.4 NM_015854 CITED2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal 2.2 NM_006079 RARA retinoic acid receptor, alpha 2.5 NM_000964 domain, 2 THBS1 thrombospondin 1 (mediates cell-cell & cell-matrix interactions) 2.5 AI812030 TPM1 tropomyosin 1 (alpha) 2.0 NM_000366 CRHR1
Recommended publications
  • Imm Catalog.Pdf

    Imm Catalog.Pdf

    $ Gene Symbol A B 3 C 4 D 9 E 10 F 11 G 12 H 13 I 14 J. K 17 L 18 M 19 N 20 O. P 22 R 26 S 27 T 30 U 32 V. W. X. Y. Z 33 A ® ® Gene Symbol Gene ID Antibody Monoclonal Antibody Polyclonal MaxPab Full-length Protein Partial-length Protein Antibody Pair KIt siRNA/Chimera Gene Symbol Gene ID Antibody Monoclonal Antibody Polyclonal MaxPab Full-length Protein Partial-length Protein Antibody Pair KIt siRNA/Chimera A1CF 29974 ● ● ADAMTS13 11093 ● ● ● ● ● A2M 2 ● ● ● ● ● ● ADAMTS20 80070 ● AACS 65985 ● ● ● ADAMTS5 11096 ● ● ● AANAT 15 ● ● ADAMTS8 11095 ● ● ● ● AATF 26574 ● ● ● ● ● ADAMTSL2 9719 ● AATK 9625 ● ● ● ● ADAMTSL4 54507 ● ● ABCA1 19 ● ● ● ● ● ADAR 103 ● ● ABCA5 23461 ● ● ADARB1 104 ● ● ● ● ABCA7 10347 ● ADARB2 105 ● ABCB9 23457 ● ● ● ● ● ADAT1 23536 ● ● ABCC4 10257 ● ● ● ● ADAT2 134637 ● ● ABCC5 10057 ● ● ● ● ● ADAT3 113179 ● ● ● ABCC8 6833 ● ● ● ● ADCY10 55811 ● ● ABCD2 225 ● ADD1 118 ● ● ● ● ● ● ABCD4 5826 ● ● ● ADD3 120 ● ● ● ABCG1 9619 ● ● ● ● ● ADH5 128 ● ● ● ● ● ● ABL1 25 ● ● ADIPOQ 9370 ● ● ● ● ● ABL2 27 ● ● ● ● ● ADK 132 ● ● ● ● ● ABO 28 ● ● ADM 133 ● ● ● ABP1 26 ● ● ● ● ● ADNP 23394 ● ● ● ● ABR 29 ● ● ● ● ● ADORA1 134 ● ● ACAA2 10449 ● ● ● ● ADORA2A 135 ● ● ● ● ● ● ● ACAN 176 ● ● ● ● ● ● ADORA2B 136 ● ● ACE 1636 ● ● ● ● ADRA1A 148 ● ● ● ● ACE2 59272 ● ● ADRA1B 147 ● ● ACER2 340485 ● ADRA2A 150 ● ● ACHE 43 ● ● ● ● ● ● ADRB1 153 ● ● ACIN1 22985 ● ● ● ADRB2 154 ● ● ● ● ● ACOX1 51 ● ● ● ● ● ADRB3 155 ● ● ● ● ACP5 54 ● ● ● ● ● ● ● ADRBK1 156 ● ● ● ● ACSF2 80221 ● ● ADRM1 11047 ● ● ● ● ACSF3 197322 ● ● AEBP1 165 ● ● ● ● ACSL4 2182 ●
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse

    Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse

    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
  • The Title of the Article

    The Title of the Article

    Mechanism-Anchored Profiling Derived from Epigenetic Networks Predicts Outcome in Acute Lymphoblastic Leukemia Xinan Yang, PhD1, Yong Huang, MD1, James L Chen, MD1, Jianming Xie, MSc2, Xiao Sun, PhD2, Yves A Lussier, MD1,3,4§ 1Center for Biomedical Informatics and Section of Genetic Medicine, Department of Medicine, The University of Chicago, Chicago, IL 60637 USA 2State Key Laboratory of Bioelectronics, Southeast University, 210096 Nanjing, P.R.China 3The University of Chicago Cancer Research Center, and The Ludwig Center for Metastasis Research, The University of Chicago, Chicago, IL 60637 USA 4The Institute for Genomics and Systems Biology, and the Computational Institute, The University of Chicago, Chicago, IL 60637 USA §Corresponding author Email addresses: XY: [email protected] YH: [email protected] JC: [email protected] JX: [email protected] XS: [email protected] YL: [email protected] - 1 - Abstract Background Current outcome predictors based on “molecular profiling” rely on gene lists selected without consideration for their molecular mechanisms. This study was designed to demonstrate that we could learn about genes related to a specific mechanism and further use this knowledge to predict outcome in patients – a paradigm shift towards accurate “mechanism-anchored profiling”. We propose a novel algorithm, PGnet, which predicts a tripartite mechanism-anchored network associated to epigenetic regulation consisting of phenotypes, genes and mechanisms. Genes termed as GEMs in this network meet all of the following criteria: (i) they are co-expressed with genes known to be involved in the biological mechanism of interest, (ii) they are also differentially expressed between distinct phenotypes relevant to the study, and (iii) as a biomodule, genes correlate with both the mechanism and the phenotype.
  • Molecular Mechanisms Involved Involved in the Interaction Effects of HCV and Ethanol on Liver Cirrhosis

    Molecular Mechanisms Involved Involved in the Interaction Effects of HCV and Ethanol on Liver Cirrhosis

    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2010 Molecular Mechanisms Involved Involved in the Interaction Effects of HCV and Ethanol on Liver Cirrhosis Ryan Fassnacht Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Physiology Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/2246 This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. Ryan C. Fassnacht 2010 All Rights Reserved Molecular Mechanisms Involved in the Interaction Effects of HCV and Ethanol on Liver Cirrhosis A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science at Virginia Commonwealth University. by Ryan Christopher Fassnacht, B.S. Hampden Sydney University, 2005 M.S. Virginia Commonwealth University, 2010 Director: Valeria Mas, Ph.D., Associate Professor of Surgery and Pathology Division of Transplant Department of Surgery Virginia Commonwealth University Richmond, Virginia July 9, 2010 Acknowledgement The Author wishes to thank his family and close friends for their support. He would also like to thank the members of the molecular transplant team for their help and advice. This project would not have been possible with out the help of Dr. Valeria Mas and her endearing
  • Cleveland Clinic Laboratories

    Cleveland Clinic Laboratories

    Cleveland Clinic Laboratories Technical Update • May 2014 Cleveland Clinic Laboratories is dedicated to keeping you updated and informed about recent testing changes. That's why we are happy to provide this technical update on a monthly basis. Recently changed tests are bolded, and could include revisions to methodology, reference range, days performed or CPT code. For your convenience, tests are listed alphabetically and the order and billing codes are provided. If you wish to compare the new information with previous test demographics, refer to the Test Directory, which can be accessed at clevelandcliniclabs.com. Deleted tests and new tests are listed separately. Please update your database as necessary. For additional detail, contact Client Services at 216.444.5755 or 800.628.6816 or via email at [email protected]. Days Performed/Reported Specimen Requirement Special InformationComponent Change Test Discontinued Reference Range Test Update Name Change Methodology Order CodeBiling Code New Test Page # Summary of Changes CPT by Test Name 3 5-Hydroxyindolacetic Acid, Urine 3 11-Deoxycorticosterone Qt, Serum / Plasma 3 25-Hydroxyvitamin D2 and D3, Serum 9 Alpha-1 Antitrypsin (SERPINA1) Targeted Genotyping 3 Alpha-1-Antitrypsin Clearance 3 Alpha-1-Antitrypsin, Stool 3 Anti IgA Antibody 3 Anti Mullerian Hormone 3 Beta Galactosidase, Leukocytes 4 Bioavailable Testosterone / SHBG, Female & Child 4 BK Virus Quantitation, Urine 12 Buprenorphine & Metabolite, Confirmation / Quant, Urine 9 Buprenorphine Quant, Urine 4 Carnitine Free & Total,
  • Edinburgh Research Explorer

    Edinburgh Research Explorer

    Edinburgh Research Explorer International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list Citation for published version: Davenport, AP, Alexander, SPH, Sharman, JL, Pawson, AJ, Benson, HE, Monaghan, AE, Liew, WC, Mpamhanga, CP, Bonner, TI, Neubig, RR, Pin, JP, Spedding, M & Harmar, AJ 2013, 'International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands', Pharmacological reviews, vol. 65, no. 3, pp. 967-86. https://doi.org/10.1124/pr.112.007179 Digital Object Identifier (DOI): 10.1124/pr.112.007179 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Pharmacological reviews Publisher Rights Statement: U.S. Government work not protected by U.S. copyright General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 1521-0081/65/3/967–986$25.00 http://dx.doi.org/10.1124/pr.112.007179 PHARMACOLOGICAL REVIEWS Pharmacol Rev 65:967–986, July 2013 U.S.
  • Supplementary Data

    Supplementary Data

    Supplemental Data A novel mouse model of X-linked nephrogenic diabetes insipidus: Phenotypic analysis and therapeutic implications Jian Hua Li, Chung-Lin Chou, Bo Li, Oksana Gavrilova, Christoph Eisner, Jürgen Schnermann, Stasia A. Anderson, Chu-Xia Deng, Mark A. Knepper, and Jürgen Wess Supplemental Methods Metabolic cage studies. Animals were maintained in mouse metabolic cages (Hatteras Instruments, Cary, NC) under controlled temperature and light conditions (12 hr light and dark cycles). Mice received a fixed daily ration of 6.5 g of gelled diet per 20 g of body weight per day. The gelled diet was composed of 4 g of Basal Diet 5755 (Test Diet, Richmond, IN), 2.5 ml of deionized water, and 65 mg agar. Preweighted drinking water was provided ad libitum during the course of the study. Mice were acclimated in the metabolic cages for 1-2 days. Urine was collected under mineral oil in preweighted collection vials for successive 24 hr periods. Analysis of GPCR expression in mouse IMCD cells via TaqMan real-time qRT-PCR. Total RNA prepared from mouse IMCD tubule suspensions was reverse transcribed as described under Experimental Procedures. Tissues from ten 10-week old C57BL/6 WT mice were collected and pooled for each individual experiment. cDNA derived from 640 ng of RNA was mixed with an equal volume of TaqMan gene expression 2 x master mix (Applied Biosystems, Foster City, CA). 100 μl-aliquots of this mixture (corresponding to 80 ng of RNA) were added to each of the 8 fill ports of a 384-well plate of a mouse GPCR array panel (Applied Biosystems).
  • Investigating Cone Photoreceptor Development Using Patient-Derived NRL Null Retinal Organoids

    Investigating Cone Photoreceptor Development Using Patient-Derived NRL Null Retinal Organoids

    ARTICLE https://doi.org/10.1038/s42003-020-0808-5 OPEN Investigating cone photoreceptor development using patient-derived NRL null retinal organoids Alyssa Kallman1,11, Elizabeth E. Capowski 2,11, Jie Wang 3, Aniruddha M. Kaushik4, Alex D. Jansen2, Kimberly L. Edwards2, Liben Chen4, Cynthia A. Berlinicke3, M. Joseph Phillips2,5, Eric A. Pierce6, Jiang Qian3, ✉ ✉ Tza-Huei Wang4,7, David M. Gamm2,5,8 & Donald J. Zack 1,3,9,10 1234567890():,; Photoreceptor loss is a leading cause of blindness, but mechanisms underlying photoreceptor degeneration are not well understood. Treatment strategies would benefit from improved understanding of gene-expression patterns directing photoreceptor development, as many genes are implicated in both development and degeneration. Neural retina leucine zipper (NRL) is critical for rod photoreceptor genesis and degeneration, with NRL mutations known to cause enhanced S-cone syndrome and retinitis pigmentosa. While murine Nrl loss has been characterized, studies of human NRL can identify important insights for human retinal development and disease. We utilized iPSC organoid models of retinal development to molecularly define developmental alterations in a human model of NRL loss. Consistent with the function of NRL in rod fate specification, human retinal organoids lacking NRL develop S- opsin dominant photoreceptor populations. We report generation of two distinct S-opsin expressing populations in NRL null retinal organoids and identify MEF2C as a candidate regulator of cone development. 1 Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, USA. 2 Waisman Center, University of Wisconsin-Madison, Madison, USA. 3 Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, USA.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • Biochemical Society Focused Meetings Proteases A

    Biochemical Society Focused Meetings Proteases A

    ORE Open Research Exeter TITLE Proteases and caspase-like activity in the yeast Saccharomyces cerevisiae. AUTHORS Wilkinson, D; Ramsdale, M JOURNAL Biochemical Society Transactions DEPOSITED IN ORE 18 November 2013 This version available at http://hdl.handle.net/10871/13957 COPYRIGHT AND REUSE Open Research Exeter makes this work available in accordance with publisher policies. A NOTE ON VERSIONS The version presented here may differ from the published version. If citing, you are advised to consult the published version for pagination, volume/issue and date of publication Biochemical Society Transactions (2011) XX, (XX-XX) (Printed in Great Britain) Biochemical Society Focused Meetings Proteases and caspase-like activity in the yeast Saccharomyces cerevisiae Derek Wilkinson and Mark Ramsdale1 Biosciences, University of Exeter, Geoffrey Pope Building, Stocker Road, Exeter, EX4 4QD Key words: Programmed cell death, apoptosis, necrosis, proteases, caspases, Saccharomyces cerevisiae. Abbreviations used: PCD, programmed cell death; ROS, reactive oxygen species; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; ER, endoplasmic reticulum; MS, mass spectrometry. 1email [email protected] Abstract A variety of proteases have been implicated in yeast PCD including the metacaspase, Mca1 and the separase Esp1, the HtrA-like serine protease Nma111, the cathepsin-like serine carboxypeptideases and a range of vacuolar proteases. Proteasomal activity is also shown to have an important role in determining cell fate, with both pro- and anti-apoptotic roles. Caspase-3, -6- and -8 like activities are detected upon stimulation of yeast PCD, but not all of this activity is associated with Mca1, implicating other proteases with caspase-like activity in the yeast cell death response.
  • Regulation and Evolutionary Origins of Repulsive

    Regulation and Evolutionary Origins of Repulsive

    REGULATION AND EVOLUTIONARY ORIGINS OF REPULSIVE GUIDANCE MOLECULE C / HEMOJUVELIN EXPRESSION: A MUSCLE-ENRICHED GENE INVOLVED IN IRON METABOLISM by Christopher John Severyn B.A. (University of California, Berkeley) 2002 A dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in BIOCHEMISTRY AND MOLECULAR BIOLOGY Presented to the Department of Biochemistry & Molecular Biology OREGON HEALTH & SCIENCE UNIVERSITY School of Medicine July 2010 Department of Biochemistry & Molecular Biology, School of Medicine OREGON HEALTH & SCIENCE UNIVERSITY _________________________________________________ CERTIFICATE OF APPROVAL _________________________________________________ This is to certify that the Ph.D. dissertation of Christopher J. Severyn has been approved by the following: __________________________ Peter Rotwein, M.D., dissertation advisor Professor of Biochemistry and Department Chair __________________________ Maureen Hoatlin, Ph.D., committee chair Associate Professor of Biochemistry __________________________ Matt Thayer, Ph.D., committee member Professor of Biochemistry __________________________ Ujwal Shinde, Ph.D., committee member Professor of Biochemistry __________________________ Jim Lundblad, M.D., Ph.D., committee member Associate Professor of Medicine and Chief of Endocrinology TABLE OF CONTENTS Page List of Tables iii List of Figures iv List of Abbreviations vii Acknowledgements xiv Publications arising from this Dissertation xvi Abstract xvii Key words xix Chapter 1: Introduction 1. 1 General Overview 2 1. 2 Expression and Regulation of RGMc 3 1. 3 Gene Regulation: Transcription from an evolutionary perspective 4 1. 4 Gene Regulation: Translation 6 1. 5 Iron Metabolism in Eukaryotes 6 1. 6 Dissertation Overview 7 Chapter 2: Repulsive Guidance Molecule Family 2. 1 Summary 15 2. 2 Introduction 16 2. 3 RGMa 16 2. 4 RGMb 21 2.
  • Datasheet A11267-1 Anti-ZNF318 Antibody

    Datasheet A11267-1 Anti-ZNF318 Antibody

    Product datasheet Anti-ZNF318 Antibody Catalog Number: A11267-1 BOSTER BIOLOGICAL TECHNOLOGY Special NO.1, International Enterprise Center, 2nd Guanshan Road, Wuhan, China Web: www.boster.com.cn Phone: +86 27 67845390 Fax: +86 27 67845390 Email: [email protected] Basic Information Product Name Anti-ZNF318 Antibody Gene Name ZNF318 Source Rabbit IgG Species Reactivity human, rat Tested Application WB, FCM, Direct ELISA Contents 500 ug/ml antibody with PBS ，0.02% NaN3 , 1 mg BSA and 50% glycerol. Immunogen E.coli-derived human ZNF318 recombinant protein (Position: E680-Q1197). Purification Immunogen affinity purified. Observed MW 290KD Dilution Ratios Western blot: 1:500-2000 Flow cytometry (FCM)： 1-3μg/1x106 cells Direct ELISA： 1:100-1000 Storage 12 months from date of receipt，-20℃ as supplied.6 months 2 to 8℃ after reconstitution. Avoid repeated freezing and thawing Background Information Zinc finger protein 318 is a protein that in humans is encoded by the ZNF318 gene. ZNF318 encodes a nuclear protein with a zinc finger motif of the Cys2-His2 type that is a novel corepressor of androgen receptor (AR). Reference Anti-ZNF318 Antibody被引用在0文献中。 暂无引用 FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC AND CLINICAL USE. 1 Product datasheet Anti-ZNF318 Antibody Catalog Number: A11267-1 BOSTER BIOLOGICAL TECHNOLOGY Special NO.1, International Enterprise Center, 2nd Guanshan Road, Wuhan, China Web: www.boster.com.cn Phone: +86 27 67845390 Fax: +86 27 67845390 Email: [email protected] Selected Validation Data Figure 1. Western blot Figure 2. Flow cytometry analysis of anti- ZNF318 analysis of A431 cell Antibody (A11267-1).